About this trial
This is an observational study performed by retrospective review of data routinely collected for patients receiving low-flow extracorporeal carbon dioxide removal (ECCO2R) therapy in intensive care units (ICUs). Our aim is to firstly, describe the local practice in terms of patient selection and technical details of clinical management related to the use of low-flow ECCO2R system, and secondly, the clinical results in terms of patient outcomes and adverse events. These findings may allow clinicians to improve the quality and safety of ECCO2R therapy provision in the ICU.
Eligibility criteria
Qualifiers
Patients supported with ECCO2R in one of the designated study sites
Admitted to the ICU between 1 Jan 2022 and 30 June 2024
Disqualifiers
Patients younger than 18 years old
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Hong Kong University
Lead sponsor
Hospital Authority, Hong Kong
Sponsor institution